GlassScriptPhysician profile
Melhem Jabbour
NPI 1851697536
$23,458.36
in general payments reported to CMS, 2019-2025
86 companies · $3,135 in 2025
The $3,135 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,711 · 2020: $2,386 · 2021: $2,424 · 2022: $5,097 · 2023: $3,322 · 2024: $4,383 · 2025: $3,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,068 · Long Term Medical Supply Or Device Loan: $682 · Education: $566 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,067.94 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $565.61 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,387.41 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $2,411.43 | 2019-2025 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $1,318.10 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $1,226.70 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Janssen Biotech, INC. | $1,109.93 | 2019-2025 | Tecvayli, Rybrevant, Darzalex |
| Pfizer INC. | $928.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $872.74 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genzyme Corporation | $820.14 | 2019-2025 | |
| Seagen INC. | $734.27 | 2019-2023 | Padcev, Adcetris |
| Celgene Corporation | $608.82 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Eisai INC. | $606.28 | 2019-2025 | |
| Genentech USA, INC. | $603.25 | 2019-2025 | Polivy, Phesgo, Tecentriq |
| Alexion Pharmaceuticals, INC. | $523.92 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $494.81 | 2019-2025 | |
| Amgen INC. | $458.32 | 2019-2023 | Lumakras, Nplate, Vectibix |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $452.60 | 2020-2025 | Xtandi, Padcev |
| Exelixis INC. | $409.38 | 2019-2025 | Cabometyx |
| Incyte Corporation | $396.75 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $391.91 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Gilead Sciences, INC. | $314.47 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $313.65 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Sobi, INC | $268.67 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $230.51 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.78 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $213.09 | 2019-2023 | Imbruvica, Epkinly |
| Novocure Gmbh | $200.00 | 2022 | |
| Lilly USA, LLC | $181.28 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Pharmacosmos Therapeutics INC. | $171.18 | 2021-2025 | Monoferric, Cosela |
| Pharmaessentia USA Corporation | $168.57 | 2022-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $162.70 | 2021-2025 | Zepzelca |
| Array Biopharma INC | $136.29 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $133.01 | 2019-2025 | Somatuline Depot, Onivyde |
| Beigene USA, INC. | $132.99 | 2020-2025 | Brukinsa |
| Morphosys, US INC. | $129.01 | 2021-2023 | Monjuvi |
| Genmab U.S., INC. | $127.19 | 2022-2025 | Epkinly, Tivdak |
| Adaptive Biotechnologies Corporation | $119.31 | 2023-2025 | Clonoseq |
| Tersera Therapeutics LLC | $114.83 | 2020-2025 | Xermelo, Zoladex |
| Regeneron Healthcare Solutions, INC. | $114.18 | 2022-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $105.73 | 2023-2025 | |
| Blueprint Medicines Corporation | $103.15 | 2020-2022 | |
| Coherus Oncology, INC. | $101.64 | 2020-2024 | |
| Karyopharm Therapeutics INC. | $98.70 | 2020-2024 | Xpovio |
| Clovis Oncology, INC. | $94.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $93.57 | 2019-2024 | Xarelto |
| Emd Serono, INC. | $92.53 | 2019-2025 | |
| Acrotech Biopharma INC. | $82.76 | 2023-2025 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $80.68 | 2019-2023 | |
| Beone Medicines USA, INC. | $71.86 | 2025 | Brukinsa |
| Foundation Medicine, INC. | $71.65 | 2019-2022 | |
| Puma Biotechnology, INC. | $68.43 | 2019-2023 | |
| Acceleron Pharma, INC. | $63.80 | 2020-2021 | |
| Dova Pharmaceuticals | $60.56 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $47.90 | 2023 | Empaveli |
| Agios Pharmaceuticals, INC. | $46.76 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $45.61 | 2020-2022 | |
| Syndax Pharmaceuticals, INC. | $45.59 | 2025 | Revuforj |
| Geron Corporation | $43.48 | 2025 | Rytelo |
| Tolmar Pharmaceuticals, INC. | $42.76 | 2022 | |
| Kite Pharma, INC. | $42.14 | 2021-2023 | |
| Epizyme, INC. | $40.63 | 2020-2021 | |
| Spectrum Pharmaceuticals INC. | $38.25 | 2023 | Rolvedon |
| Stemline Therapeutics INC. | $37.31 | 2024-2025 | Orserdu |
| Legend Biotech USA INC. | $34.30 | 2025 | Carvykti |
| Verastem, INC. | $33.66 | 2019-2025 | Avmapki Fakzynja Co-Pack |
| Sun Pharmaceutical Industries INC. | $32.22 | 2022-2024 | |
| Cti Biopharma Corp. | $26.28 | 2022 | |
| Caris Mpi, INC. | $24.58 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $23.14 | 2023 | Krazati |
| Immunocore Limited | $22.30 | 2024 | Kimmtrak |
| Sumitomo Pharma America, INC. | $21.99 | 2025 | Orgovyx |
| Organon LLC | $21.94 | 2021 | |
| Taiho Oncology, INC. | $20.84 | 2023 | |
| Fennec Pharmaceuticals, INC. | $18.58 | 2025 | Fyarro |
| Mylan Institutional INC. | $18.28 | 2019 | |
| Tolmar, INC. | $16.25 | 2023 | |
| Recordati_rare_diseases_inc. | $15.50 | 2025 | Enjaymo |
| Azurity Pharmaceuticals, INC. | $14.90 | 2025 | Vivimusta |
| Eusa Pharma (US) LLC | $14.87 | 2022 | |
| Kyowa Kirin, INC. | $14.18 | 2024 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $14.12 | 2023 | Akynzeo |
| Amag Pharmaceuticals, INC. | $13.57 | 2021 | |
| Adc Therapeutics America, INC. | $12.89 | 2022 | |
| Deciphera Pharmaceuticals INC. | $12.76 | 2021 | |
| G1 Therapeutics, INC. | $11.66 | 2022 | |
| Partner Therapeutics, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
Kisqali $1,055Lynparza $780Keytruda $658Enhertu $587Reblozyl $382Tecvayli $277Xtandi $276Doptelet $256Welireg $223Jakafi $220Padcev $215Opdivo $206Lenvima $198Carvykti $193Adcetris $186Venclexta $177Rybrevant $176Scemblix $172Imbruvica $170Darzalex $167Brukinsa $164Epkinly $154Elrexfio $151Besremi $151Injectafer $150Inlyta $149Polivy $146Lutathera $140Trodelvy $136Talzenna $129Mektovi $128Ultomiris $124Clonoseq $119Sarclisa $117Calquence $117Phesgo $111Braftovi $109Tecentriq $109Orgovyx $108Cabometyx $106Pluvicto $104Libtayo $98.36Lorbrena $96.31Eliquis $92.85Pomalyst $92.50Fabhalta $90.07Tukysa $89.35Ibrance $88.58Zepzelca $88.37Tibsovo $84.68Piqray $83.26Beleodaq $82.76Monoferric $80.55Jaypirca $80.17Fruzaqla $79.97Bosulif $79.22Tasigna $78.97Xalkori $76.35Soliris $74.99Tavalisse $64.34Keytruda Qlex $62.03Lunsumio $61.60Opdualag $60.29Monjuvi $55.44Xpovio $54.14Xermelo $53.59Rozlytrek $52.45Alecensa $52.45Somatuline Depot $49.66Onivyde $49.66Promacta $49.32Rezlidhia $48.81Empaveli $47.90Gavreto $47.60Lumakras $46.96Paxlovid $45.82Revuforj $45.59Comirnaty $43.85Rytelo $43.48Udenyca $39.05Rolvedon $38.25Iclusig $37.84Orserdu $37.31Zoladex $33.49Jevtana $33.26Nplate $31.80Vectibix $31.80Xgeva $31.80Oxbryta $30.90Enjaymo $30.86Columvi $30.44Perjeta $29.19Jemperli $28.90Zejula $28.90Ojjaara $28.83Akynzeo $28.24Bavencio $26.93Talvey $26.19Erleada $26.09Mi Cancer Seek $24.58
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melhem Jabbour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.